Titration of amlodipine to higher doses: A comparison of Asian and Western experience

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 695-701

  Kario, Kazuomi ^a   Robbins, Jeffery ^b   Jeffers, Barrett W ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b PFIZER INC   (United States)

Author keywords

Amlodipine; Asia; Hypertension

Indexed keywords

AMLODIPINE;

ADULT; ADVERSE OUTCOME; ARTICLE; ASIAN; BACKACHE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HOT FLUSH; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; MIDDLE AGED; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; RACE DIFFERENCE; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; RHINOPHARYNGITIS; SKIN DISEASE; SOFT TISSUE DISEASE; SYSTOLIC BLOOD PRESSURE; THORAX DISEASE; VASCULAR DISEASE;

AMLODIPINE; ASIA; HYPERTENSION;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS, PHASE III AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASODILATOR AGENTS; WESTERN WORLD;

EID: 84889796286     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S50077     Document Type: Article

References (41)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
2. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18): 1291-1297.
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913.
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998-3007.
5. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
6. Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008;51(2):393-398.
7. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
8. Costanzo P, Perrone-Filardi P, Petretta M, et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175, 634 patients. J Hypertens. 2009;27(6):1136-1151.
9. Takagi H, Umemoto T. Revisiting evidence of blood pressure-dependent and independent effects of amlodipine on the risk of stroke. J Clin Hypertens (Greenwich). 2011;13(10):781-782.
10. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview. Hypertension. 2007;50(1):181-188.
11. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
12. Daskalopoulou SS, Khan NA, Quinn RR, et al. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2012;28(3):270-287.
13. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18(6): 308-347.
14. Wang JG, Kario K, Lau T, et al. Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: a scientific statement from the Asian Pacific Heart Association. Hypertens Res. 2011;34(4):423-430.
15. Martiniuk AL, Lee CM, Lawes CM, et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens. 2007;25(1):73-79.
16. Lawes CM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21(4):707-716.
17. Perkovic V, Huxley R, Wu Y, Prabhakaran D, MacMahon S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension. 2007;50(6):991-997.
18. Fogari R, Mugellini A, Derosa G. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. JRAAS. 2007;8(3):139-144.
19. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217-2225.
20. Kario K, Odawara M, Kimura K, Node K. Nearly half of uncontrolled hypertensive patients could be controlled by high-dose titration of amlodipine in the clinical setting: the ACHIEVE study. Curr Hypertens Rev. 2011;7:102-110.
21. Uno H, Ishikawa J, Hoshide S, et al. Effects of strict blood pressure control by a long-acting calcium channel blocker on brain natriuretic peptide and urinary albumin excretion rate in Japanese hypertensive patients. Hypertens Res. 2008;31(5):887-896.
22. Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich). 2003;5(5):330-335.
23. Chockalingam A, Campbell NR, Fodor JG. Worldwide epidemic of hypertension. Can J Cardiol. 2006;22(7):553-555.
24. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-1357.
25. Langdon C. Treatment of hypertension in patients ≥65 years of age: experience with amlodipine. Clin Ther. 2000;22(12):1473-1482.
26. Tallian KB, Nahata MC, Turman MA, Mahan JD, Hayes JR, Mentser MI. Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol. 1999;13(4):304-310.
27. Valcárcel Y, Jiménez R, Hernández V, Arístegui R, Gil A. Efficacy and safety of amlodipine: a comparative study of hypertensive patients treated at primary-and specialised-care centres. Clin Drug Investig. 2006;26(3):125-133.
28. Sowunmi A, Walker O, Salako LA. Amlodipine as monotherapy in hypertensive Africans: clinical efficacy and safety studies. Afr J Med Med Sci. 1996;25(3):213-216.
29. Jorgensen B, Simonsen S, Endresen K, et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES). J Am Coll Cardiol. 2000;35(3):592-599.
30. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis. 2002;165(2):191-199.
31. Hoshide S, Fukutomi M, Eguchi K, Watanabe T, Kabutoya T, Kario K. Change in high-sensitive cardiac troponin T on hypertensive treatment. Clin Exp Hypertens. 2013;35(1):40-44.
32. Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension. 1996;27(1):130-135.
33. Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension. 2001;38(4):852-857.
34. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107(10): 1401-1406.
35. Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. Hypertension. 2010;56(5):765-773.
36. Ishimitsu T, Minami J, Kawano Y, Numabe A, Takishita S, Matsuoka H. Amlodipine, a long-acting calcium channel blocker, attenuates morning blood pressure rise in hypertensive patients. Clin Exp Pharmacol Physiol. 1999;26(7):500-504.
37. Eguchi K, Kario K, Shimada K. Effects of long-acting ACE inhibitor (temocapril) and long-acting Ca channel blocker (amlodipine) on 24-h ambulatory BP in elderly hypertensive patients. J Hum Hypertens. 2001;15(9):643-648.
38. Fukutomi M, Hoshide S, Eguchi K, Watanabe T, Shimada K, Kario K. Differential effects of strict blood pressure lowering by losartan/hydrochlorothiazide combination therapy and high-dose amlodipine monotherapy on microalbuminuria: the ALPHABET study. J Am Soc Hypertens. 2012;6(1):73-82.
39. Ishikawa J, Hoshide S, Eguchi K, Ishikawa S, Shimada K, Kario K. Nighttime home blood pressure and the risk of hypertensive target organ damage. Hypertension. 2012;60(4):921-928.
40. Kario K, Shimada K. Differential effects of amlodipine on ambulatory blood pressure in elderly hypertensive patients with different nocturnal reductions in blood pressure. Am J Hypertens. 1997;10(3):261-268.
41. Nielsen. Headaches, colds and backache-most common health complaints: Nielsen Global Survey. 2007. Available from: http://nz.nielsen.com/news/OTC_Aug07.shtml. Accessed July 29, 2013.